TY - JOUR
T1 - Tolterodine Extended Release With or Without Tamsulosin in Men With Lower Urinary Tract Symptoms Including Overactive Bladder Symptoms
T2 - Effects of Prostate Size
AU - Roehrborn, Claus
AU - Kaplan, Steven A.
AU - Jones, J. Stephen
AU - Wang, Joseph T.
AU - Bavendam, Tamara
AU - Guan, Zhonghong
N1 - Funding Information:
Financial disclosures : I certify that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: The study was funded by Pfizer Inc. Claus Roehrborn has served as a consultant to Pfizer Inc, AMS, spectrum, Aeterna Zentaris, Lilly, GSK, and Sanofi Aventis, and an investigator for AMS, Aeterna Zentaris, and GSK. Dr. Kaplan has served as a consultant for Pfizer Inc, Astellas, and Allergan. Dr. Jones has served as a consultant for Cook Medical, an investigator for Photocare, and a lecturer for Pfizer Inc, Abbott, and Endocare. Joseph T. Wang, Zhonghong Guan, and Tamara Bavendam are employed by Pfizer Inc.The study protocol and all amendments were approved by the appropriate Institutional Review Boards and/or Independent Ethics Committees at each center.
Funding Information:
Funding/Support and role of the sponsor: The study was funded by Pfizer Inc. Editorial support was provided Colin P. Mitchell, PhD at Complete Healthcare Communications, Inc. and was funded by Pfizer Inc. Pfizer participated in the design of the study, collection of data, management, analysis, and interpretation of the data. Pfizer Inc. approved the manuscript.
Copyright:
Copyright 2009 Elsevier B.V., All rights reserved.
PY - 2009/2
Y1 - 2009/2
N2 - Background: Some men with lower urinary tract symptoms (LUTS) including overactive bladder (OAB) symptoms may benefit from antimuscarinic therapy, with or without an α-adrenergic antagonist. Objectives: To evaluate the safety and efficacy of tolterodine extended release (ER), tamsulosin, or tolterodine ER+tamsulosin in men meeting symptom entry criteria for OAB and prostatic enlargement trials, stratified by prostate size. Design, setting, and participants: Subjects with an International Prostate Symptom Score (IPSS) ≥12; frequency and urgency, with or without urgency urinary incontinence; postvoid residual volume (PVR) <200 mL; and maximum urinary flow rate (Qmax) >5 mL/s were randomized to receive placebo, tolterodine ER (4 mg), tamsulosin (0.4 mg), or tolterodine ER+tamsulosin for 12 wk. Data were stratified by median baseline prostate volume (<29 mL vs ≥29 mL). Measurements: Endpoints included week 12 changes in bladder diary variables, IPSS scores, and safety variables. Results and limitations: Among men with larger prostates, tolterodine ER+tamsulosin significantly improved frequency (p = 0.001); urgency (p = 0.006); and IPSS total (p = 0.001), storage (p < 0.001), and voiding scores (p < 0.013). Tamsulosin significantly improved IPSS voiding scores (p = 0.030). Among men with smaller prostates, tolterodine ER significantly improved frequency (p = 0.016), UUI episodes (p = 0.036), and IPSS storage scores (p = 0.005). Tolterodine ER+tamsulosin significantly improved frequency (p = 0.001) and IPSS storage scores (p = 0.018). Tamsulosin significantly improved nocturnal frequency (p = 0.038) and IPSS voiding (p = 0.036) and total scores (p = 0.044). There were no clinically or statistically significant changes in Qmax or PVR; incidence of acute urinary retention (AUR) was low in all groups (≤2%). Conclusions: Men with smaller prostates and moderate-to-severe LUTS including OAB symptoms benefited from tolterodine ER. Therapy with tolterodine ER+tamsulosin was effective regardless of prostate size. Tolterodine ER, with or without tamsulosin, was well tolerated and not associated with increased incidence of AUR.
AB - Background: Some men with lower urinary tract symptoms (LUTS) including overactive bladder (OAB) symptoms may benefit from antimuscarinic therapy, with or without an α-adrenergic antagonist. Objectives: To evaluate the safety and efficacy of tolterodine extended release (ER), tamsulosin, or tolterodine ER+tamsulosin in men meeting symptom entry criteria for OAB and prostatic enlargement trials, stratified by prostate size. Design, setting, and participants: Subjects with an International Prostate Symptom Score (IPSS) ≥12; frequency and urgency, with or without urgency urinary incontinence; postvoid residual volume (PVR) <200 mL; and maximum urinary flow rate (Qmax) >5 mL/s were randomized to receive placebo, tolterodine ER (4 mg), tamsulosin (0.4 mg), or tolterodine ER+tamsulosin for 12 wk. Data were stratified by median baseline prostate volume (<29 mL vs ≥29 mL). Measurements: Endpoints included week 12 changes in bladder diary variables, IPSS scores, and safety variables. Results and limitations: Among men with larger prostates, tolterodine ER+tamsulosin significantly improved frequency (p = 0.001); urgency (p = 0.006); and IPSS total (p = 0.001), storage (p < 0.001), and voiding scores (p < 0.013). Tamsulosin significantly improved IPSS voiding scores (p = 0.030). Among men with smaller prostates, tolterodine ER significantly improved frequency (p = 0.016), UUI episodes (p = 0.036), and IPSS storage scores (p = 0.005). Tolterodine ER+tamsulosin significantly improved frequency (p = 0.001) and IPSS storage scores (p = 0.018). Tamsulosin significantly improved nocturnal frequency (p = 0.038) and IPSS voiding (p = 0.036) and total scores (p = 0.044). There were no clinically or statistically significant changes in Qmax or PVR; incidence of acute urinary retention (AUR) was low in all groups (≤2%). Conclusions: Men with smaller prostates and moderate-to-severe LUTS including OAB symptoms benefited from tolterodine ER. Therapy with tolterodine ER+tamsulosin was effective regardless of prostate size. Tolterodine ER, with or without tamsulosin, was well tolerated and not associated with increased incidence of AUR.
KW - Benign prostatic hyperplasia
KW - Lower urinary tract symptoms
KW - Overactive bladder
KW - Prostate volume
KW - Quality of life
KW - Tamsulosin
KW - Tolterodine extended release
UR - http://www.scopus.com/inward/record.url?scp=57649158625&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=57649158625&partnerID=8YFLogxK
U2 - 10.1016/j.eururo.2008.06.032
DO - 10.1016/j.eururo.2008.06.032
M3 - Article
C2 - 18583022
AN - SCOPUS:57649158625
SN - 0302-2838
VL - 55
SP - 472
EP - 481
JO - European urology
JF - European urology
IS - 2
ER -